Analyst Ratings For Global Blood Therapeutics (NASDAQ:GBT)
Today, William Blair initiated coverage on Global Blood Therapeutics (NASDAQ:GBT) with a Outperform with a price target of $80.00.
Some recent analyst ratings include
- 1/23/2018-William Blair initiated coverage with a Outperform rating.
- 12/15/2017-Wedbush Reiterated Rating of Outperform.
Recent Insider Trading Activity For Global Blood Therapeutics (NASDAQ:GBT)
Global Blood Therapeutics (NASDAQ:GBT) has insider ownership of 5.30% and institutional ownership of 85.71%.
- On 1/17/2018 Jung Choi, Insider, sold 3,000 with an average share price of $52.85 per share and the total transaction amounting to $158,550.00.
- On 1/10/2018 Peter Radovich, Insider, sold 15,000 with an average share price of $50.00 per share and the total transaction amounting to $750,000.00.
- On 12/19/2017 Perceptive Advisors Llc, Major Shareholder, bought 175,000 with an average share price of $38.00 per share and the total transaction amounting to $6,650,000.00.
- On 12/18/2017 Jung Choi, Insider, sold 3,000 with an average share price of $36.55 per share and the total transaction amounting to $109,650.00.
- On 10/30/2017 Peter Radovich, VP, sold 12,500 with an average share price of $35.00 per share and the total transaction amounting to $437,500.00.
- On 10/27/2017 Charles J Homcy, Director, sold 70,000 with an average share price of $33.97 per share and the total transaction amounting to $2,377,900.00.
- On 10/17/2017 Jung Choi, Insider, sold 3,000 with an average share price of $32.65 per share and the total transaction amounting to $97,950.00.
Recent Trading Activity for Global Blood Therapeutics (NASDAQ:GBT)
Shares of Global Blood Therapeutics closed the previous trading session at 57.15 up +0.80 1.42% with 59.39500045776367 shares trading hands.